What's Happening?
Researchers at the University of Illinois Chicago are investigating the potential of lidocaine, a common anesthetic, to prevent the spread of pancreatic cancer cells during surgery. Their study focuses
on circulating tumor cells (CTCs) that enter the bloodstream during tumor removal. Using microfluidic technology, the team aims to isolate these cells and explore lidocaine's ability to inhibit their metastatic potential. This research could lead to new strategies for reducing cancer recurrence.
Why It's Important?
Pancreatic cancer is one of the deadliest forms of cancer, with high recurrence rates and low survival rates. The ability to prevent metastasis during surgery could significantly improve patient outcomes. Lidocaine's potential anti-metastatic properties offer a novel approach to cancer treatment, highlighting the importance of perioperative care in oncology. This research could pave the way for new therapeutic interventions that enhance survival rates for pancreatic cancer patients.
